PPARα Ligands as Antitumorigenic and Antiangiogenic Agents
2008
PPARα Ligands as Cancer Fighters
publication
10 minutes
Evidence: moderate
Author Information
Author(s): Ambra Pozzi, Jorge H. Capdevila
Primary Institution: Vanderbilt University
Hypothesis
PPARα ligands may serve as antitumorigenic and antiangiogenic agents.
Conclusion
PPARα ligands can inhibit tumor growth and angiogenesis, suggesting their potential as cancer treatment options.
Supporting Evidence
- PPARα ligands have been shown to reduce tumor cell proliferation in various cancer types.
- Activation of PPARα can inhibit angiogenesis by downregulating proangiogenic factors.
- Studies indicate that PPARα ligands may have limited toxicity compared to traditional cancer therapies.
Takeaway
PPARα is a special protein that can help stop cancer from growing and spreading by blocking blood vessel formation.
Methodology
This review analyzes existing studies on PPARα ligands and their effects on cancer and angiogenesis.
Potential Biases
Potential bias due to the focus on rodent studies which may not fully translate to human outcomes.
Limitations
The long-term effects of PPARα ligands on cancer in humans are not fully understood.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website